A team led by scientists from The Scripps Research Institute and the International AIDS Vaccine Initiative has unveiled a new technique for vaccine design that could be particularly useful against HIV and other fast-changing viruses.
From trying on the first set of scrubs to guiding a patient toward a good death, a new book features a Penn Nursing professor and student on quintessential moments in nursing – stories that have been largely untold.
For HIV-infected patients whose disease is well-controlled by modern treatment, the risk of death is not significantly higher than in the general population, according to a study published in AIDS, official journal of the International AIDS Society. AIDS is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.
Nanoparticles carrying a toxin found in bee venom can destroy human immunodeficiency virus (HIV) while leaving surrounding cells unharmed, researchers at Washington University School of Medicine in St. Louis have shown. The finding is an important step toward developing a vaginal gel that may prevent the spread of HIV, the virus that causes AIDS.
A study that analyzed data from more than 82,000 veterans suggests that infection with the human immunodeficiency virus (HIV) was associated with an increased risk of acute myocardial infarction (AMI, heart attack) beyond what is explained by recognized risk factors, according to a report published Online First by JAMA Internal Medicine, a JAMA Network publication.
Infectious disease experts at Johns Hopkins have found that among people infected with the hepatitis C virus (HCV), co-infection with HIV, speeds damage and scarring of liver tissue by almost a decade.
The results of two important studies have been published in the March issue of AIDS, the official journal of the International AIDS Society. One study notes that screening for HIV should be performed more frequently—up to every three months for the highest-risk patients, while low-risk groups to be tested every three years. A second study demonstrates a link between heavy drinking and risky behaviors for men who have sex with men (MSM). AIDS is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.
Johns Hopkins scientists have identified 25 human proteins “stolen” by HIV-1 viruses that may be critical to their ability to infect new cells. The proteins were shared by HIV-1 viruses coming from two very different types of infected cells. The research could help in building diagnostic tools and novel treatment strategies to fight HIV infection.
A research team from Case Western Reserve University School of Medicine has discovered an approach that could make gene therapy dramatically more effective for patients.
Led by professor Eric Arts, PhD, the scientists discovered that the process of gene therapy is missing essential elements thereby reducing the effectiveness of this treatment. Re-introducing this element into their model system suggests that improvements for gene therapy areon the horizon.
The findings are detailed in the article, “A new genomic RNA packaging element in retroviruses and the interplay with ribosomal frameshifting,” published today in the journal Cell Host & Microbe.
Researchers have identified a protein with broad virus-fighting properties that could be used as a weapon against deadly human pathogenic viruses such as HIV, Ebola, and others designated "priority pathogens" for national biosecurity purposes by the National Institute of Allergy and Infectious Disease. .
Facebook and other social networking technologies be effective tools for preventing HIV infection among at-risk groups. African American and Latino men who have sex with men voluntarily used health-related Facebook groups to discuss such things as HIV prevention and to request HIV testing kits.
Texas Biomed scientists in San Antonio have found that moderate gum disease in an animal model exposed to an AIDS- like virus had more viral variants causing infection and greater inflammation. Both of these features have potential negative implications in long term disease progression, including other kinds of infections, the researchers say in a new report.
One of four people with HIV/AIDS is 50 or older, yet they are far more likely to be diagnosed when they are in the later stages of infection. Government mistrust and conspiracy fears are deeply ingrained in them and these concerns often deter these vulnerable individuals from getting tested for HIV.
Columbia Biomedical Engineering Professor Samuel Sia has taken his innovative lab-on-a-chip and developed a way to not only check a patient’s HIV status anywhere in the world with just a finger prick, but also synchronize the results automatically and instantaneously with central health-care records—10 times faster than the benchtop ELISA.
New York University College of Nursing (NYUCN) researchers Michele G. Shedlin, PhD, and Joyce K. Anastasi, PhD, DrNP, FAAN, LAc, published a paper, “Use of Complementary and Alternative Medicines and Supplements by Mexican-Origin Patients in a U.S.–Mexico Border HIV Clinic,” in the on-line version of the Journal of the Association of Nurses in AIDS Care.
A team of researchers based at Johns Hopkins has decoded a system that makes certain types of immune cells impervious to HIV infection. The system’s two vital components are high levels of a molecule that becomes embedded in viral DNA like a code written in invisible ink, and an enzyme that, when it reads the code, switches from repairing the DNA to chopping it up into unusable pieces.
New research appearing online today in Clinical Chemistry, the journal of AACC, shows that a handheld mobile device can check patients’ HIV status with just a finger prick, and synchronize the results in real time with electronic health records. This technology takes a step toward providing remote areas of the world with diagnostic services traditionally available only in centralized healthcare settings.
With a new $3.4 million grant from the National Institutes of Health, the University of Missouri is leading a team of researchers who want to stay a step ahead of HIV by finding new pathways for shutting down the virus. The scientists are developing new compounds designed to target an enzyme in HIV called RNase H, which has escaped the reach of existing drugs.
Switching the type of syringe used by people who inject drugs could help curb HIV transmission in countries with injection-driven epidemics within eight years, according to a new article by researchers at RTI International and Futures Institute.
Lausanne, Switzerland, 17th December 2012--- A study published today online in The Journal of Experimental Medicine has identified the population of CD4 T cells serving as the major reservoir for HIV infected cells and as the primary cell site for HIV replication and production in infected patients. The study was led by Prof. Giuseppe Pantaleo and Dr. Matthieu Perreau at the Division of Immunology and Allergy and at the Swiss Vaccine Research Institute, Lausanne University Hospital, Lausanne, Switzerland.
A new study by NYU School of Medicine researchers suggests that an existing HIV drug called maraviroc could be a potential therapy for Staphylococcus aureus, a notorious and deadly pathogen linked to hundreds of thousands of hospitalizations each year. Their study is published online this week in Nature.
Can treatment with modern anti-HIV drugs help fight hunger for HIV-infected patients in Africa? Starting antiretroviral therapy for HIV reduces "food insecurity" among patients in Uganda, suggests a study published online by the journal AIDS, official journal of the International AIDS Society. AIDS is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.
Road networks and geographic factors affecting "spatial accessibility" have a major impact on the spread of HIV across sub-Saharan Africa, according to a study published online by the journal AIDS, official journal of the International AIDS Society. AIDS is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.
Electrically spun cloth with nanometer-sized fibers show promise as a cheap, versatile platform to simultaneously offer contraception and prevent HIV. New funding from the Bill & Melinda Gates Foundation will further test the system's versatility and feasibility.
Statement by South Bronx-based Health People Executive Director Chris Norwood on the Obama Administration's PEPFAR "Blueprint for and AIDS Free World" and its implications for U.S. AIDS policy.
The New York Academy of Sciences and the Johns Hopkins Bloomberg School of Public Health present the conference “New Paradigms of Risk and Protection: Understanding the HIV Epidemics among Gay and Bisexual Men” on December 7, 2012. The Conference will explore how novel and more effective HIV prevention programs for men who have sex with men (MSM) could help to hamper epidemics, which are expanding in low, middle, and high income countries, among this population.
To mark World AIDS Day on Saturday, Dec. 1, 2012, more than 1,000 new posters from one of the world’s largest AIDS education poster collections have been digitized and put online by archivists at the University of Rochester.
The Texas Biomedical Research Institute in San Antonio has applied for a patent for a genetically-engineered vaccine strategy to prevent HIV infection that targets the outer layers of body structures that are the first sites of contact with the virus.
Cognitive training exercises can help improve mental processing speed and ability to complete daily tasks in middle-age and older adults with HIV, a population that is experiencing cognitive impairments at a higher rate than those without the disease.
After screening more than 2,300 drugs for their ability to halt the growth of breast cancer cells, Johns Hopkins researchers have discovered that the anti-HIV drug nelfinavir slows the progress of HER2-positive tumor cells, even if they are resistant to other breast cancer drugs.
Methadone reduces the risk of HIV transmission in people who inject drugs (PWID), as reported by an international team of researchers in a paper published today in the online edition of the British Medical Journal
The way the body metabolizes a commonly prescribed anti-retroviral drug that is used long term by patients infected with HIV may contribute to cognitive impairment by damaging nerve cells, a new Johns Hopkins research suggests.
Same-sex partners and inconsistent condom use were among the major risk factors for HIV infection among U.S. Navy and Marines personnel during the "Don't Ask, Don't Tell" (DADT) era, reports a study in the October 1 issue of JAIDS: Journal of Acquired Immune Deficiency Syndromes. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.
Biologists at UC San Diego have unraveled the anti-viral mechanism of a human gene that may explain why some people infected with HIV have much higher amounts of virus in their bloodstreams than others.
Researchers at the University of Kentucky have embarked on a five-year study that aims to lower behavioral risks of HIV/AIDS and hepatitis C (HCV) among disadvantaged, rural women in Appalachian Kentucky.
HIV-positive people who progress to full blown AIDS slower than others carry a rare immune gene variant. Even among these people the speed of disease progression varies widely. A possible key to that variation is a killer T-cell immune response that targets a section of the HIV protein called IW9.
Less than half of community-based substance abuse treatment programs in the United States currently make HIV testing available on-site or through referral. A new study led by researchers at Weill Cornell Medical College shows the cost-effectiveness of integrating on-site rapid HIV testing into drug treatment programs.
The World Health Organization (WHO) is about to embark on a new strategy to prevent AIDS in South Africa, a country thought to have more people with HIV/AIDS than any other country in the world. Using mathematical modeling, the WHO predicts this strategy could completely eliminate HIV in South Africa within a decade. Alas, researchers at UCLA respectively disagree, suggesting the WHO has left out key considerations. Their own model suggests a different approach.
Between 2000 and 2008, the proportion of HIV-infected patients in the U.S. receiving effective treatment known as highly active antiretroviral therapy (HAART) increased, and HIV-infected patients appeared to be less infectious and have healthier immune systems at death.
Pooling data from thousands of tests of the antiviral activity of more than 20 commonly used anti-HIV drugs, AIDS experts at Johns Hopkins and Harvard universities have developed what they say is the first accurate computer simulation to explain drug effects. Already, the model clarifies how and why some treatment regimens fail in some patients who lack evidence of drug resistance.
Like recruiters pitching military service to a throng of people, scientists are developing drugs to recruit disease-fighting proteins present naturally in everyone’s blood in medicine’s war on infections, cancer and a range of other diseases. They reported on the latest advances in this new approach here today at the 244th National Meeting & Exposition of the American Chemical Society, the world’s largest scientific society.
UCSF researchers found that poor HIV-infected individuals living in San Francisco are significantly more likely to visit emergency rooms and to have hospital stays if they lack access to food of sufficient quality and quantity for a healthy life.